concept

CRISPR

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about CRISPR: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

15Connections
11Hypotheses
4Analyses
7Outgoing
8Incoming
4Experiments
4Debates

No summary available yet. View on Wiki →

No AI portrait yet

💡 Concept Info
NameCRISPR
Key Genes/ProteinsCell-type-specific essential genes, Disease-causing mutations with integrated reporters, NURR1, PITX3, neuronal identity transcription factors, PGC1A, SIRT1, FOXO3, mitochondrial biogenesis genes
Related DiseasesAmyotrophic Lateral Sclerosis
Linked Hypotheses12 hypotheses

Wiki Pages (13)

Knowledge base pages for this entity

Canonical Page

CRISPR Gene Editing for Neurodegenerative Diseases

technology · 1209 words

CRISPR Gene Editing for Parkinson's Disease

therapeutic · 2794 words

Section 107: CRISPR-Based Therapies in CBS/PSP

therapeutic · 2585 words

CRISPR Gene Editing in Neurodegeneration

technology · 2558 words

CRISPRi Epigenetic Silencing of SNCA for Parkinson's Disease

idea · 2184 words

CRISPR Gene Editing for Neurodegeneration

therapeutic · 1859 words

Pathway Diagram

graph TD
    CRISPR[CRISPR]
    CRISPR -->|targets| Central_Nervous_System[Central Nervous System]
    CRISPR -->|mediates| Epigenetic_Modifications[Epigenetic Modifications]
    CRISPR -->|targets| APOE[APOE]
    CRISPR -->|promotes| Metabolic_Reprogramming[Metabolic Reprogramming]
    CRISPR -->|edits| Mitochondrial_Genome[Mitochondrial Genome]
    CRISPR -->|targets| Adult_Neurons[Adult Neurons]
    CRISPR -->|activates| Misfolded_Protein_Aggregates[Misfolded Protein Aggregates]
    CRISPR -->|inhibits| MSH3[MSH3]
    CRISPR -->|inhibits| PMS1[PMS1]
    CRISPR -->|treats| Amyotrophic_Lateral_Sclerosis[Amyotrophic Lateral Sclerosis]
    SDA_2026_04_02_gap_crispr_neur[SDA-2026-04-02-gap-crispr-neurodegeneration-20260402] -->|investigates| CRISPR
    Viral_Vector[Viral Vector] -->|mediates| CRISPR
    exosome[exosome] -->|interacts| CRISPR
    blood_brain_barrier[blood brain barrier] -->|inhibits| CRISPR
    Cell_type_specific_essential_g[Cell-type-specific essential genes] -->|co_associated_with| CRISPR
    PGC1A__SIRT1__FOXO3__mitochond[PGC1A, SIRT1, FOXO3, mitochondrial biogenesis genes] -->|co_associated_with| CRISPR
    NURR1__PITX3__neuronal_identit[NURR1, PITX3, neuronal identity transcription factors] -->|co_associated_with| CRISPR
    Disease_causing_mutations_with[Disease-causing mutations with integrated reporters] -->|co_associated_with| CRISPR

Outgoing (7)

TargetRelationTypeStr
Epigenetic Modificationsmediatesprocess0.95
Central Nervous Systemtargetsbrain_region0.95
APOEtargetsgene0.90
Metabolic Reprogrammingpromotesprocess0.90
Adult Neuronstargetscell_type0.85

Incoming (8)

SourceRelationTypeStr
SDA-2026-04-02-gap-crispr-neurodegeneration-20260402investigatesanalysis0.95
exosomeinteracts_withcompound0.85
Viral Vectormediatescompound0.85
blood brain barrierinhibitsbrain_region0.80
Disease-causing mutations with integrated reportersco_associated_withgene0.30

Targeting Hypotheses (11)

Hypotheses where this entity is a therapeutic target

HypothesisScoreDiseaseAnalysis
Epigenetic Memory Reprogramming via CRISPRa-Mediated Chromat 0.690 neurodegeneration CRISPR-based therapeutic approaches for
Context-Dependent CRISPR Activation in Specific Neuronal Sub 0.682 neurodegeneration CRISPR-based therapeutic approaches for
Temporal CAG Repeat Stabilization via CRISPR-Mediated DNA Mi 0.681 neurodegeneration CRISPR-based therapeutic approaches for
CRISPR-Mediated Mitochondrial Genome Editing for Complex I D 0.681 neurodegeneration CRISPR-based therapeutic approaches for
Acid-Degradable LNP-Mediated Prenatal CRISPR Intervention fo 0.638 neurodegeneration CRISPR-based therapeutic approaches for
Conditional CRISPR Kill Switches for Aberrant Protein Cleara 0.624 neurodegeneration CRISPR-based therapeutic approaches for
Cholesterol-CRISPR Convergence Therapy for Neurodegeneration 0.622 neurodegeneration CRISPR-based therapeutic approaches for
Trinucleotide Repeat Sequestration via CRISPR-Guided RNA Tar 0.613 neurodegeneration CRISPR-based therapeutic approaches for
Metabolic Reprogramming via Coordinated Multi-Gene CRISPR Ci 0.599 neurodegeneration CRISPR-based therapeutic approaches for
Programmable Neuronal Circuit Repair via Epigenetic CRISPR 0.596 neurodegeneration CRISPR-based therapeutic approaches for
Multi-Modal CRISPR Platform for Simultaneous Editing and Mon 0.596 neurodegeneration CRISPR-based therapeutic approaches for

Mentioning Analyses (4)

Scientific analyses that reference this entity

What molecular mechanisms explain how KCNJ2 inhibition mitigates TBI-induced neu

neurodegeneration | 2026-04-13 | 0 hypotheses

How can CRISPR systems achieve persistent therapeutic effects while avoiding chr

gene therapy | 2026-04-11 | 0 hypotheses

CRISPR-based therapeutic approaches for neurodegenerative diseases

neurodegeneration | 2026-04-03 | 14 hypotheses Top: 0.803

CRISPR-based therapeutic approaches for neurodegenerative diseases

neurodegeneration | 2026-04-02 | 0 hypotheses

Experiments (4)

Experimental studies targeting or related to this entity

ExperimentTypeDiseaseScoreFeasibilityModelStatusEst. Cost
Acteoside treatment in LPS-induced SALI mouse model validation sepsis-associated acute lung i 0.900 0.00 LPS-induced SALI mouse model proposed N/A
Nrf2 inhibitor ML385 mechanism validation experiment exploratory sepsis-associated acute lung i 0.850 0.00 RAW264.7 cells and/or mouse mo proposed N/A
Acteoside effects on RAW264.7 macrophage cells exploratory sepsis-associated acute lung i 0.850 0.00 RAW264.7 cells proposed N/A
CRISPR Gene Correction Approaches for CBS/PSP clinical Parkinson's Disease 0.400 0.50 human proposed $6,550,000

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMIDAuthorsJournalYearCitations
Autophagy and ALS: mechanistic insights and therapeutic implications. [PMID:34057020] Chua JP, De Calbiac H, Kabashi E, Barmad Autophagy 2022 2
Exploring Parkinson's through the Lens of Genomics and Bioinformatics. [PMID:39929729] Menon V Cold Spring Harb Perspect Med 2026 0
Mismatch repair MLH complexes make distinct contributions to post-replicative mi [PMID:41648604] Casazza KM, Williams GM, Johengen L, Kel bioRxiv 2026 0
A Simple Method for RNA-Seq of Manually Isolated Chromatophores in Oryzias Fishe [PMID:41805030] Goda M, Miyagi A, Sugiwaka K, Watanabe M Dev Growth Differ 2026 0
Cell-type resolved protein atlas of brain lysosomes identifies SLC45A1-associate [PMID:41576950] ["Ghoochani A", "Heiby J", "Rawat E", "M Cell 2026 0
Decoding Alzheimer's genetic risk through intercellular communication in the hum [PMID:41707523] Lish AM, Young-Pearse TL Current opinion in neurobiolog 2026 0
Neuromodulatory role and therapeutic potential of N 6 -methyladenosine RNA methy [PMID:40618260] Zhang J, Ma W, Liu R, Li X, Yuan Z, Chen Neural regeneration research 2026 0
Single-Cell Atlas of Transcription and Chromatin States Reveals Regulatory Progr [PMID:41676679] Xie Y, Chang L, Zhong G, Rink JA, Báez-B bioRxiv : the preprint server 2026 0
Targeting a Shared Mitophagy Regulator: The SIRT1-FOXO3-DEPP1 Axis Underpins the [PMID:41743852] Zhang Y, Guo X, Wang Q, Xiao L, Liu Q, G Research (Washington, D.C.) 2026 0
Long somatic DNA-repeat expansion drives neurodegeneration in Huntington's disea [PMID:39824182] ["Handsaker R", "Kashin S", "Reed N", "T Cell 2025 0
Canagliflozin attenuates neurodegeneration and ameliorates dyskinesia through ta [PMID:39700958] ["Abdelaziz A", "Rasheed N", "Zaki H", " International immunopharmacolo 2025 0
Metabolic rewiring prevents neurodegeneration caused by chronic mitochondrial dy [PMID:41151583] Richhariya S, Shin D, Schlichting M, Ros Current biology : CB 2025 0
HMGCR genetic variability in Parkinson's disease in a Spanish cohort: associatio [PMID:41037108] Díaz-Belloso R, Martín-Bornez M, Macías- Journal of neurology 2025 0
Nurr1 modulators - a patent review (2019-present). [PMID:40481732] ["Egner M", "Merk D"] Expert opinion on therapeutic 2025 0
VDAC2 loss elicits tumour destruction and inflammation for cancer therapy. [PMID:40108474] Yuan S, Sun R, Shi H, Chapman NM, Hu H, Nature 2025 0
Focused ultrasound widely broadens AAV-delivered Cas9 distribution and activity. [PMID:39893321] Gumusgoz E, Kasiri S, Youssef I, Verma M Gene therapy 2025 0
Cell-Type Resolved Protein Atlas of Brain Lysosomes Identifies SLC45A1-Associate [PMID:39464040] ["Ghoochani A", "Heiby J", "Rawat E", "M bioRxiv : the preprint server 2024 0
25-Hydroxycholesterol attenuates tumor necrosis factor alpha-induced blood-brain [PMID:39181516] Loiola RA, Nguyen C, Dib S, Saint-Pol J, Biochimica et biophysica acta. 2024 0
Cholinergic neurodegeneration and cholesterol metabolism dysregulation by consti [PMID:37900943] ["Comaposada-Bar\u00f3 R", "Benito-Mart\ Frontiers in molecular neurosc 2023 0
The role of Nurr1-miR-30e-5p-NLRP3 axis in inflammation-mediated neurodegenerati [PMID:37990334] ["Li T", "Tan X", "Tian L", "Jia C", "Ch Journal of neuroinflammation 2023 0

Debates (4)

Multi-agent debates referencing this entity

The debate highlighted that long-term CRISPR expression triggers immune response

closed · Rounds: 4 · Score: 0.50 · 2026-04-18

The study identifies KCNJ2 as a therapeutic target through CRISPR screening but

closed · Rounds: 4 · Score: 0.71 · 2026-04-16

Evaluate the potential of CRISPR/Cas9 and related gene editing technologies for

closed · Rounds: 4 · Score: 0.95 · 2026-04-03

Evaluate the potential of CRISPR/Cas9 and related gene editing technologies for

closed · Rounds: 4 · Score: 0.90 · 2026-04-02